首页 > 最新文献

Pigment Cell & Melanoma Research最新文献

英文 中文
Molecular skin fluorescence imaging: A tool for evaluating early melanoma development 分子皮肤荧光成像:评估早期黑色素瘤发展的工具。
IF 4.3 3区 医学 Q2 CELL BIOLOGY Pub Date : 2024-01-04 DOI: 10.1111/pcmr.13159
Amit Shachaf, Kevin Manbeck, Guang Yang, Catherine Shachaf

A novel approach to melanoma diagnosis—in vivo molecular skin fluorescence imaging (mSFI)—was developed to identify premalignant changes in the form of tissue remodeling related to melanoma development in humans by imaging the proximal microenvironment of lesions. The method was tested using a fluorescent peptide (ORL-1) which binds to αvβ3 integrin, a molecule associated with invasive melanoma development. A cut off score of 7 was established, differentiating melanomas from nonmelanoma nevi with 100% sensitivity, and 95.7% specificity, while identifying dysplastic nevi with the potential for melanoma development.

我们开发了一种诊断黑色素瘤的新方法--体内分子皮肤荧光成像(mSFI)--通过对病变近端微环境成像,以组织重塑的形式识别与人类黑色素瘤发展相关的恶性前变化。该方法使用一种与αvβ3整合素结合的荧光肽(ORL-1)进行测试,αvβ3整合素是一种与黑色素瘤浸润性发展相关的分子。结果表明,7 分的临界值能以 100% 的灵敏度和 95.7% 的特异性将黑色素瘤与非黑色素瘤痣区分开来,同时还能识别出有可能发展成黑色素瘤的发育不良痣。
{"title":"Molecular skin fluorescence imaging: A tool for evaluating early melanoma development","authors":"Amit Shachaf,&nbsp;Kevin Manbeck,&nbsp;Guang Yang,&nbsp;Catherine Shachaf","doi":"10.1111/pcmr.13159","DOIUrl":"10.1111/pcmr.13159","url":null,"abstract":"<p>A novel approach to melanoma diagnosis—in vivo molecular skin fluorescence imaging (mSFI)—was developed to identify premalignant changes in the form of tissue remodeling related to melanoma development in humans by imaging the proximal microenvironment of lesions. The method was tested using a fluorescent peptide (ORL-1) which binds to αvβ3 integrin, a molecule associated with invasive melanoma development. A cut off score of 7 was established, differentiating melanomas from nonmelanoma nevi with 100% sensitivity, and 95.7% specificity, while identifying dysplastic nevi with the potential for melanoma development.</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 3","pages":"372-377"},"PeriodicalIF":4.3,"publicationDate":"2024-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.13159","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive molecular findings in primary malignant melanoma of the esophagus: A multicenter study 食管原发性恶性黑色素瘤的综合分子研究结果:一项多中心研究。
IF 4.3 3区 医学 Q2 CELL BIOLOGY Pub Date : 2023-12-29 DOI: 10.1111/pcmr.13157
Ling Deng, Hai-Yun Wang, Chun-Fang Hu, Xiao-Yun Liu, Kuntai Jiang, Juan-Juan Yong, Xiao-Yan Wu, Kai-Hua Guo, Fang Wang

Primary malignant melanoma of the esophagus (PMME) is an extremely rare but highly aggressive malignancy with a poor prognosis. Due to the scarcity of driver gene alterations, there is a need for more clinical data to comprehensively depict its molecular alterations. This study reviewed 26 PMME cases from three medical centers. Hybrid capture-based targeted sequencing of 295 and 1021 genes was performed in 14 and 12 cases, respectively. We found that PMME patients had a relatively low tumor mutation burden (median, 2.88 mutations per Mb) and were simultaneously accompanied by mutations in genes such as KIT (6/26, 23%), TP53 (6/26, 23%), SF3B1 (4/26, 15%), and NRAS (3/26, 12%). KIT, NRAS, and BRAF were mutually exclusive, and SF3B1 co-occurred with KIT mutation and amplification. The most common pathways affected were the mitogen-activated protein kinases and DNA damage response (DDR) pathways. Stage IV was a risk factor for both progression-free survival (hazard ratio [HR] = 5.14, 95% confidence interval [CI] = 1.32–19.91) and overall survival (OS), HR = 4.33, 95% CI = 1.22–15.30). Treatment with immune-checkpoint inhibitors (ICIs) was an independent factor for favorable OS (HR = 0.10, 95% CI = 0.01–0.91). Overall, PMME is a complex malignancy with diverse gene alterations, especially with harboring DDR alterations for potentially response from ICIs.

食管原发性恶性黑色素瘤(PMME)是一种极为罕见但侵袭性极强的恶性肿瘤,预后极差。由于缺乏驱动基因的改变,因此需要更多的临床数据来全面描述其分子改变。本研究回顾了来自三个医疗中心的26例PMME病例。分别对14例和12例患者的295个和1021个基因进行了基于混合捕获的靶向测序。我们发现,PMME 患者的肿瘤突变负荷相对较低(中位数为每 Mb 2.88 个突变),同时伴有 KIT(6/26,23%)、TP53(6/26,23%)、SF3B1(4/26,15%)和 NRAS(3/26,12%)等基因的突变。KIT、NRAS和BRAF相互排斥,SF3B1与KIT突变和扩增同时存在。最常见的受影响途径是丝裂原活化蛋白激酶和DNA损伤应答(DDR)途径。IV期是无进展生存期(危险比[HR] = 5.14,95%置信区间[CI] = 1.32-19.91)和总生存期(OS)(HR = 4.33,95%置信区间[CI] = 1.22-15.30)的危险因素。接受免疫检查点抑制剂(ICIs)治疗是获得良好OS的独立因素(HR = 0.10,95% CI = 0.01-0.91)。总之,PMME是一种复杂的恶性肿瘤,存在多种基因改变,尤其是DDR改变,可能对ICIs产生反应。
{"title":"Comprehensive molecular findings in primary malignant melanoma of the esophagus: A multicenter study","authors":"Ling Deng,&nbsp;Hai-Yun Wang,&nbsp;Chun-Fang Hu,&nbsp;Xiao-Yun Liu,&nbsp;Kuntai Jiang,&nbsp;Juan-Juan Yong,&nbsp;Xiao-Yan Wu,&nbsp;Kai-Hua Guo,&nbsp;Fang Wang","doi":"10.1111/pcmr.13157","DOIUrl":"10.1111/pcmr.13157","url":null,"abstract":"<p>Primary malignant melanoma of the esophagus (PMME) is an extremely rare but highly aggressive malignancy with a poor prognosis. Due to the scarcity of driver gene alterations, there is a need for more clinical data to comprehensively depict its molecular alterations. This study reviewed 26 PMME cases from three medical centers. Hybrid capture-based targeted sequencing of 295 and 1021 genes was performed in 14 and 12 cases, respectively. We found that PMME patients had a relatively low tumor mutation burden (median, 2.88 mutations per Mb) and were simultaneously accompanied by mutations in genes such as <i>KIT</i> (6/26, 23%), <i>TP53</i> (6/26, 23%), <i>SF3B1</i> (4/26, 15%), and <i>NRAS</i> (3/26, 12%). <i>KIT</i>, <i>NRAS</i>, and <i>BRAF</i> were mutually exclusive, and <i>SF3B1</i> co-occurred with <i>KIT</i> mutation and amplification. The most common pathways affected were the mitogen-activated protein kinases and DNA damage response (DDR) pathways. Stage IV was a risk factor for both progression-free survival (hazard ratio [HR] = 5.14, 95% confidence interval [CI] = 1.32–19.91) and overall survival (OS), HR = 4.33, 95% CI = 1.22–15.30). Treatment with immune-checkpoint inhibitors (ICIs) was an independent factor for favorable OS (HR = 0.10, 95% CI = 0.01–0.91). Overall, PMME is a complex malignancy with diverse gene alterations, especially with harboring DDR alterations for potentially response from ICIs.</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 3","pages":"363-371"},"PeriodicalIF":4.3,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.13157","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139072803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Small extracellular vesicle-based human melanocyte and melanoma signature 基于细胞外小泡的人类黑色素细胞和黑色素瘤特征。
IF 3.9 3区 医学 Q2 CELL BIOLOGY Pub Date : 2023-12-29 DOI: 10.1111/pcmr.13158
Andrea Agüera-Lorente, Ainhoa Alonso-Pardavila, María Larrinaga, María Dolores Boyano, Esperanza González, Juan Manuel Falcón-Pérez, Aintzane Asumendi, Aintzane Apraiz

Intercellular communication is a cell-type and stimulus-dependent event driven not only by soluble factors but also by extracellular vesicles (EVs). EVs include vesicles of different size and origin that contain a myriad of molecules. Among them, small EVs (sEV; <200 nm) have been shown to modulate not just regional cell responses but also distant organ behavior. In cancer, distant organ modulation by sEVs has been associated to disease dissemination, which is one of the main concerns in melanoma. Description of broadly conserved alterations in sEV-contained molecules represents a strategy to identify key modifications in cellular communication as well as new disease biomarkers. Here, we characterize proteomes of cutaneous melanocyte and melanoma-derived sEVs to deepen on the landscape of normal and disease-related cell communication. Results reveal the presence of unique protein signatures for melanocytes and melanoma cells that reflect cellular transformation-related profound modifications. Melanocyte-derived sEVs are enriched in oxidative metabolism (e.g., aconitase 2, ACO2) or pigmentation (e.g., tyrosinase, TYR) related proteins while melanoma-derived sEVs reflect a generalized decrease in mature melanocytic markers (e.g., melanoma antigen recognized by T-cells 1, MART-1, also known as MLANA) and an increase in epithelial to mesenchymal transition (EMT)-related adhesion molecules such as tenascin C (TNC).

细胞间通信是一种依赖于细胞类型和刺激的事件,不仅由可溶性因子驱动,还由细胞外囊泡 (EV) 驱动。EV包括不同大小和来源的囊泡,其中含有大量分子。其中,小囊泡(sEV;
{"title":"Small extracellular vesicle-based human melanocyte and melanoma signature","authors":"Andrea Agüera-Lorente,&nbsp;Ainhoa Alonso-Pardavila,&nbsp;María Larrinaga,&nbsp;María Dolores Boyano,&nbsp;Esperanza González,&nbsp;Juan Manuel Falcón-Pérez,&nbsp;Aintzane Asumendi,&nbsp;Aintzane Apraiz","doi":"10.1111/pcmr.13158","DOIUrl":"10.1111/pcmr.13158","url":null,"abstract":"<p>Intercellular communication is a cell-type and stimulus-dependent event driven not only by soluble factors but also by extracellular vesicles (EVs). EVs include vesicles of different size and origin that contain a myriad of molecules. Among them, small EVs (sEV; &lt;200 nm) have been shown to modulate not just regional cell responses but also distant organ behavior. In cancer, distant organ modulation by sEVs has been associated to disease dissemination, which is one of the main concerns in melanoma. Description of broadly conserved alterations in sEV-contained molecules represents a strategy to identify key modifications in cellular communication as well as new disease biomarkers. Here, we characterize proteomes of cutaneous melanocyte and melanoma-derived sEVs to deepen on the landscape of normal and disease-related cell communication. Results reveal the presence of unique protein signatures for melanocytes and melanoma cells that reflect cellular transformation-related profound modifications. Melanocyte-derived sEVs are enriched in oxidative metabolism (e.g., aconitase 2, ACO2) or pigmentation (e.g., tyrosinase, TYR) related proteins while melanoma-derived sEVs reflect a generalized decrease in mature melanocytic markers (e.g., melanoma antigen recognized by T-cells 1, MART-1, also known as MLANA) and an increase in epithelial to mesenchymal transition (EMT)-related adhesion molecules such as tenascin C (TNC).</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 5","pages":"569-582"},"PeriodicalIF":3.9,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.13158","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139072804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis 恶性黑色素瘤患者在接受免疫检查点抑制剂治疗后接受达卡巴嗪和替莫唑胺治疗的作用:病例系列和荟萃分析。
IF 4.3 3区 医学 Q2 CELL BIOLOGY Pub Date : 2023-12-29 DOI: 10.1111/pcmr.13156
Viktoria Rydén, Ali Inan El-Naggar, Anthoula Koliadi, Cecilia Olsson Ladjevardi, Evangelos Digkas, Antonios Valachis, Gustav J. Ullenhag

Dacarbazine (DTIC) and its oral counterpart temozolomide (TMZ) have been the most used agents in advanced malignant melanoma (MM) patients and they are still used routinely. The preferred first line treatment, immune checkpoint inhibitors (CPIs) might shape the tumor and the tumor microenvironment, possibly affecting the response to subsequent therapies. The aim of this study was to investigate the treatment effect of DTIC/TMZ in MM patients after CPI therapy in a consecutive patient cohort and through systematic literature review and meta-analysis. Thirty-five patients with advanced MM treated with DTIC/TMZ after previous CPI therapy in three Swedish regions between 2017 and 2021 were recognized and seven case series studies were identified through systematic database review. Pooled data from all 345 patients showed a median real-world progression-free survival (rwPFS) of 1.9 months and overall survival (OS) of 6.0 months. Three of these studies were included in a meta-analysis comparing DTIC/TMZ after CPI treatment, versus no previous immunotherapy, showing no statistically significant differences in rwPFS or OS but higher real-world response rate to chemotherapy for the prior-CPI treated group (Odds Ratio: 2.24; 95% Confidence Interval: 1.04–4.86). The current study supports consideration of DTIC/TMZ in later line of treatment in the immunotherapy era.

达卡巴嗪(DTIC)及其口服对应药物替莫唑胺(TMZ)一直是晚期恶性黑色素瘤(MM)患者最常用的药物,目前仍在常规使用。作为首选的一线治疗药物,免疫检查点抑制剂(CPIs)可能会影响肿瘤和肿瘤微环境,从而可能影响对后续疗法的反应。本研究旨在通过系统性文献回顾和荟萃分析,研究DTIC/TMZ对接受CPI治疗后的MM患者的治疗效果。2017年至2021年间,瑞典三个地区的35名晚期MM患者在既往接受CPI治疗后接受了DTIC/TMZ治疗,通过系统性数据库回顾确定了7项病例系列研究。所有345名患者的汇总数据显示,中位真实世界无进展生存期(rwPFS)为1.9个月,总生存期(OS)为6.0个月。其中三项研究被纳入一项荟萃分析,比较了 CPI 治疗后的 DTIC/TMZ 与既往未接受过免疫治疗的患者,结果显示 rwPFS 或 OS 无统计学差异,但既往接受过 CPI 治疗的患者组对化疗的实际反应率更高(比值比:2.24;95% 置信区间:1.04-4.86)。目前的研究支持在免疫疗法时代考虑将 DTIC/TMZ 作为晚期治疗方案。
{"title":"The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis","authors":"Viktoria Rydén,&nbsp;Ali Inan El-Naggar,&nbsp;Anthoula Koliadi,&nbsp;Cecilia Olsson Ladjevardi,&nbsp;Evangelos Digkas,&nbsp;Antonios Valachis,&nbsp;Gustav J. Ullenhag","doi":"10.1111/pcmr.13156","DOIUrl":"10.1111/pcmr.13156","url":null,"abstract":"<p>Dacarbazine (DTIC) and its oral counterpart temozolomide (TMZ) have been the most used agents in advanced malignant melanoma (MM) patients and they are still used routinely. The preferred first line treatment, immune checkpoint inhibitors (CPIs) might shape the tumor and the tumor microenvironment, possibly affecting the response to subsequent therapies. The aim of this study was to investigate the treatment effect of DTIC/TMZ in MM patients after CPI therapy in a consecutive patient cohort and through systematic literature review and meta-analysis. Thirty-five patients with advanced MM treated with DTIC/TMZ after previous CPI therapy in three Swedish regions between 2017 and 2021 were recognized and seven case series studies were identified through systematic database review. Pooled data from all 345 patients showed a median real-world progression-free survival (rwPFS) of 1.9 months and overall survival (OS) of 6.0 months. Three of these studies were included in a meta-analysis comparing DTIC/TMZ after CPI treatment, versus no previous immunotherapy, showing no statistically significant differences in rwPFS or OS but higher real-world response rate to chemotherapy for the prior-CPI treated group (Odds Ratio: 2.24; 95% Confidence Interval: 1.04–4.86). The current study supports consideration of DTIC/TMZ in later line of treatment in the immunotherapy era.</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 3","pages":"352-362"},"PeriodicalIF":4.3,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.13156","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139072809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical, histological, and molecular differences in melanoma due to different TERT promoter mutations subtypes. A retrospective cross-sectional study in 684 melanoma patients 不同 TERT 启动子突变亚型导致的黑色素瘤临床、组织学和分子差异。684例黑色素瘤患者的回顾性横断面研究。
IF 4.3 3区 医学 Q2 CELL BIOLOGY Pub Date : 2023-12-28 DOI: 10.1111/pcmr.13155
Esperanza Manrique-Silva, Millán-Esteban David, Aguerralde-Martin Maider, Zaida García-Casado, Ruggero Moro, Celia Requena, Victor Través, Amaya Virós, Rajiv Kumar, Eduardo Nagore

Differences in survival according to the pTERT mutation subtypes (−124C > T, −146C > T, and tandem −138_139CC > TT) have been observed. The present study aimed to describe the clinical as the histopathological and molecular cutaneous melanoma features according to the presence of the three most prevalent pTERT mutation subtypes (−124C > T, −146C > T, and tandem −138_139CC > TT). A retrospective cross-sectional study including 684 patients was designed, and a Partial Least-Squares Discriminant Analysis (PLS-DA) was performed. After the PSL-DA, it was observed that the tandem −138_139CC > TT subtype differs from the other subtypes. The model demonstrated that the −124C > T and the −138_139 CC > TT subtypes were associated with fast-growing melanomas (OR 0.5, CI 0.29–0.86, p = .012) and with Breslow >2 mm (OR 0.6, CI 0.37–0.97, p = .037), compared to the −146C > T mutation. Finally, the −124C > T appeared to be more associated with the presence of TILs (non-brisk) than the −146C > T (OR 0.6, CI 0.40–1.01, p = .05). These findings confirmed that the −124C > T and the tandem −138_139 CC > TT subtypes are both highly associated with the presence of features of aggressiveness; however, only the −124C > T was highly associated with TILs. This difference could explain the worse survival rate associated with the tandem −138_139CC > TT mutations.

根据pTERT突变亚型(-124C > T、-146C > T和串联-138_139CC > TT)的不同,生存率也存在差异。本研究旨在根据三种最常见的 pTERT 突变亚型(-124C > T、-146C > T 和串联 -138_139CC > TT)描述皮肤黑色素瘤的临床、组织病理学和分子特征。研究人员设计了一项包括 684 名患者的回顾性横断面研究,并进行了部分最小二乘判别分析(PLS-DA)。经过 PSL-DA 分析,发现串联 -138_139CC > TT 亚型与其他亚型不同。模型显示,与 -146C > T 突变相比,-124C > T 和 -138_139 CC > TT 亚型与快速生长的黑色素瘤(OR 0.5,CI 0.29-0.86,p = .012)和 Breslow >2 mm(OR 0.6,CI 0.37-0.97,p = .037)相关。最后,与-146C > T相比,-124C > T似乎与TILs(非风险)的存在更相关(OR 0.6,CI 0.40-1.01,p = .05)。这些发现证实,-124C > T 和串联 -138_139 CC > TT 亚型都与侵袭性特征的存在高度相关;然而,只有 -124C > T 与 TILs 高度相关。这种差异可以解释为什么串联-138_139CC > TT突变的生存率较低。
{"title":"Clinical, histological, and molecular differences in melanoma due to different TERT promoter mutations subtypes. A retrospective cross-sectional study in 684 melanoma patients","authors":"Esperanza Manrique-Silva,&nbsp;Millán-Esteban David,&nbsp;Aguerralde-Martin Maider,&nbsp;Zaida García-Casado,&nbsp;Ruggero Moro,&nbsp;Celia Requena,&nbsp;Victor Través,&nbsp;Amaya Virós,&nbsp;Rajiv Kumar,&nbsp;Eduardo Nagore","doi":"10.1111/pcmr.13155","DOIUrl":"10.1111/pcmr.13155","url":null,"abstract":"<p>Differences in survival according to the <i>pTERT</i> mutation subtypes (−124C &gt; T, −146C &gt; T, and tandem −138_139CC &gt; TT) have been observed. The present study aimed to describe the clinical as the histopathological and molecular cutaneous melanoma features according to the presence of the three most prevalent <i>pTERT</i> mutation subtypes (−124C &gt; T, −146C &gt; T, and tandem −138_139CC &gt; TT). A retrospective cross-sectional study including 684 patients was designed, and a Partial Least-Squares Discriminant Analysis (PLS-DA) was performed. After the PSL-DA, it was observed that the tandem −138_139CC &gt; TT subtype differs from the other subtypes. The model demonstrated that the −124C &gt; T and the −138_139 CC &gt; TT subtypes were associated with fast-growing melanomas (OR 0.5, CI 0.29–0.86, <i>p</i> = .012) and with Breslow &gt;2 mm (OR 0.6, CI 0.37–0.97, <i>p</i> = .037), compared to the −146C &gt; T mutation. Finally, the −124C &gt; T appeared to be more associated with the presence of TILs (non-brisk) than the −146C &gt; T (OR 0.6, CI 0.40–1.01, <i>p</i> = .05). These findings confirmed that the −124C &gt; T and the tandem −138_139 CC &gt; TT subtypes are both highly associated with the presence of features of aggressiveness; however, only the −124C &gt; T was highly associated with TILs. This difference could explain the worse survival rate associated with the tandem −138_139CC &gt; TT mutations.</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 3","pages":"343-351"},"PeriodicalIF":4.3,"publicationDate":"2023-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139047913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overview of current melanoma therapies 当前黑色素瘤疗法概述
IF 3.9 3区 医学 Q2 CELL BIOLOGY Pub Date : 2023-12-08 DOI: 10.1111/pcmr.13154
Anna Fateeva, Kevinn Eddy, Suzie Chen

Melanoma is the most aggressive type of skin cancer and is responsible for the majority of deaths from skin cancer. Therapeutic advances in the last few decades, notably the development of novel targeted therapies and immunotherapies have significantly improved patient outcomes; nonetheless, these options remain limited due to the onset of resistance to treatment modalities and relapse. In this review, we focus on the available therapeutic options, their benefits, and limitations.

黑色素瘤是最具侵袭性的皮肤癌,也是造成大多数皮肤癌患者死亡的原因。过去几十年的治疗进展,特别是新型靶向疗法和免疫疗法的开发,极大地改善了患者的预后;然而,由于对治疗模式产生抗药性和复发,这些选择仍然有限。在这篇综述中,我们将重点介绍现有的治疗方案、它们的优势和局限性。
{"title":"Overview of current melanoma therapies","authors":"Anna Fateeva,&nbsp;Kevinn Eddy,&nbsp;Suzie Chen","doi":"10.1111/pcmr.13154","DOIUrl":"10.1111/pcmr.13154","url":null,"abstract":"<p>Melanoma is the most aggressive type of skin cancer and is responsible for the majority of deaths from skin cancer. Therapeutic advances in the last few decades, notably the development of novel targeted therapies and immunotherapies have significantly improved patient outcomes; nonetheless, these options remain limited due to the onset of resistance to treatment modalities and relapse. In this review, we focus on the available therapeutic options, their benefits, and limitations.</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 5","pages":"562-568"},"PeriodicalIF":3.9,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.13154","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138563761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Myron Gordon Award Lecture 2023: Painting the neural crest: How studying pigment cells illuminates neural crest cell biology 迈伦戈登奖讲座2023:绘画神经嵴:如何研究色素细胞照亮神经嵴细胞生物学。
IF 3.9 3区 医学 Q2 CELL BIOLOGY Pub Date : 2023-11-27 DOI: 10.1111/pcmr.13147
Robert N. Kelsh

It has been 30 (!!) years since I began working on zebrafish pigment cells, as a postdoc in the laboratory of Prof. Christiane Nüsslein-Volhard. There, I participated in the first large-scale mutagenesis screen in zebrafish, focusing on pigment cell mutant phenotypes. The isolation of colourless, shady, parade and choker mutants allowed us (as a postdoc in Prof. Judith Eisen's laboratory, and then in my own laboratory at the University of Bath since 1997) to pursue my ambition to address long-standing problems in the neural crest field. Thus, we have studied how neural crest cells choose individual fates, resulting in our recent proposal of a new, and potentially unifying, model which we call Cyclical Fate Restriction, as well as addressing how pigment cell patterns are generated. A key feature of our work in the last 10 years has been the use of mathematical modelling approaches to clarify our biological models and to refine our interpretations. None of this would have been possible without a hugely talented group of laboratory members and other collaborators from around the world—it has been, and I am sure will continue to be, a pleasure and privilege to work with you all!

自从我在Christiane n sslein- volhard教授的实验室做博士后开始研究斑马鱼色素细胞以来,已经有30年了。在那里,我参与了斑马鱼的第一次大规模诱变筛选,重点是色素细胞突变表型。对无色、暗色、游行和颈链突变体的隔离使我们(作为朱迪思·艾森教授实验室的博士后,然后从1997年开始在巴斯大学我自己的实验室)能够追求我的抱负,解决神经嵴领域的长期问题。因此,我们研究了神经嵴细胞如何选择个体命运,导致我们最近提出了一个新的,潜在的统一模型,我们称之为周期性命运限制,以及解决色素细胞模式是如何产生的。在过去十年中,我们工作的一个关键特征是使用数学建模方法来澄清我们的生物模型并改进我们的解释。如果没有一群才华横溢的实验室成员和来自世界各地的其他合作者,这一切都不可能实现——我相信,与你们所有人一起工作是一种快乐和荣幸!
{"title":"Myron Gordon Award Lecture 2023: Painting the neural crest: How studying pigment cells illuminates neural crest cell biology","authors":"Robert N. Kelsh","doi":"10.1111/pcmr.13147","DOIUrl":"10.1111/pcmr.13147","url":null,"abstract":"<p>It has been 30 (!!) years since I began working on zebrafish pigment cells, as a postdoc in the laboratory of Prof. Christiane Nüsslein-Volhard. There, I participated in the first large-scale mutagenesis screen in zebrafish, focusing on pigment cell mutant phenotypes. The isolation of <i>colourless</i>, <i>shady</i>, <i>parade</i> and <i>choker</i> mutants allowed us (as a postdoc in Prof. Judith Eisen's laboratory, and then in my own laboratory at the University of Bath since 1997) to pursue my ambition to address long-standing problems in the neural crest field. Thus, we have studied how neural crest cells choose individual fates, resulting in our recent proposal of a new, and potentially unifying, model which we call Cyclical Fate Restriction, as well as addressing how pigment cell patterns are generated. A key feature of our work in the last 10 years has been the use of mathematical modelling approaches to clarify our biological models and to refine our interpretations. None of this would have been possible without a hugely talented group of laboratory members and other collaborators from around the world—it has been, and I am sure will continue to be, a pleasure and privilege to work with you all!</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 5","pages":"555-561"},"PeriodicalIF":3.9,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.13147","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138443318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk factors for sentinel lymph node metastasis in Korean acral and non-acral melanoma patients 韩国肢端和非肢端黑色素瘤患者前哨淋巴结转移的危险因素。
IF 4.3 3区 医学 Q2 CELL BIOLOGY Pub Date : 2023-11-27 DOI: 10.1111/pcmr.13153
Jee Yong Song, Young Jae Ryu, Ho Kyun Lee, Dong Hoon Lee, Yoo Duk Choi, Hyun Jeong Shim, Sook Jung Yun

Breslow thickness, ulceration, and mitotic rate are well-known prognostic factors for sentinel lymph node (SLN) metastasis in cutaneous melanoma. We investigated risk factors, including especially the degree of pigmentation, for SLN metastasis in Korean melanoma patients. We enrolled 158, composed of Korean 107 acral and 51 non-acral melanoma patients who underwent SLN biopsy. Clinicopathologic features such as Breslow thickness, ulceration, mitotic rate, and the degree of pigmentation were evaluated. The recurrence-free survival (RFS) rate and date of recurrence were determined. Fifty-four patients (34.2%) had a positive SLN biopsy result. In a multivariate analysis, Breslow thickness (odds ratio [OR] 1.93; 95% confidence interval [CI], 1.12–3.47; p = .022) and heavy pigmentation (OR 13.14; 95% CI, 2.96–95.20, p = .002) were associated with SLN metastasis. Positive SLN patients had a higher rate of loco-regional and/or distant recurrence (hazard ratio 6.32; 95% CI, 3.39–11.79; p < .001). Heavy pigmentation was associated with poor RFS. Heavy pigmentation is an independent predictor of SLN metastasis in both acral and non-acral melanoma. Our results suggest the need for in-depth SLN evaluation of cutaneous melanoma patients with heavy pigmentation and provide clinicians with important information for determining patient prognosis.

皮肤黑色素瘤前哨淋巴结(SLN)转移的预后因素有丝分裂率、溃疡和乳腺厚度。我们调查了韩国黑色素瘤患者SLN转移的危险因素,特别是色素沉着程度。我们招募了158名接受SLN活检的韩国患者,包括107名肢端黑色素瘤患者和51名非肢端黑色素瘤患者。评估临床病理特征,如brreslow厚度,溃疡,有丝分裂率和色素沉着程度。测定无复发生存率(RFS)和复发日期。54例(34.2%)患者活检结果为SLN阳性。在多变量分析中,brreslow厚度(优势比[OR] 1.93;95%置信区间[CI], 1.12-3.47;p = 0.022)和重度色素沉着(OR 13.14;95% CI, 2.96 ~ 95.20, p = 0.002)与SLN转移相关。SLN阳性患者有较高的局部和/或远处复发率(危险比6.32;95% ci, 3.39-11.79;p
{"title":"Risk factors for sentinel lymph node metastasis in Korean acral and non-acral melanoma patients","authors":"Jee Yong Song,&nbsp;Young Jae Ryu,&nbsp;Ho Kyun Lee,&nbsp;Dong Hoon Lee,&nbsp;Yoo Duk Choi,&nbsp;Hyun Jeong Shim,&nbsp;Sook Jung Yun","doi":"10.1111/pcmr.13153","DOIUrl":"10.1111/pcmr.13153","url":null,"abstract":"<p>Breslow thickness, ulceration, and mitotic rate are well-known prognostic factors for sentinel lymph node (SLN) metastasis in cutaneous melanoma. We investigated risk factors, including especially the degree of pigmentation, for SLN metastasis in Korean melanoma patients. We enrolled 158, composed of Korean 107 acral and 51 non-acral melanoma patients who underwent SLN biopsy. Clinicopathologic features such as Breslow thickness, ulceration, mitotic rate, and the degree of pigmentation were evaluated. The recurrence-free survival (RFS) rate and date of recurrence were determined. Fifty-four patients (34.2%) had a positive SLN biopsy result. In a multivariate analysis, Breslow thickness (odds ratio [OR] 1.93; 95% confidence interval [CI], 1.12–3.47; <i>p</i> = .022) and heavy pigmentation (OR 13.14; 95% CI, 2.96–95.20, <i>p</i> = .002) were associated with SLN metastasis. Positive SLN patients had a higher rate of loco-regional and/or distant recurrence (hazard ratio 6.32; 95% CI, 3.39–11.79; <i>p</i> &lt; .001). Heavy pigmentation was associated with poor RFS. Heavy pigmentation is an independent predictor of SLN metastasis in both acral and non-acral melanoma. Our results suggest the need for in-depth SLN evaluation of cutaneous melanoma patients with heavy pigmentation and provide clinicians with important information for determining patient prognosis.</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 3","pages":"332-342"},"PeriodicalIF":4.3,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138443319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MitoCur-1 induces ferroptosis to reverse vemurafenib resistance in melanoma through inhibition of USP14 MitoCur-1诱导铁下垂,通过抑制USP14逆转黑素瘤的vemurafenib耐药性。
IF 4.3 3区 医学 Q2 CELL BIOLOGY Pub Date : 2023-11-20 DOI: 10.1111/pcmr.13150
Gege Li, Changlong Zhou, Lu Wang, Yalong Zheng, Bo Zhou, Guoyan Li, Zhongyu Ma, Peng Sun, Yuantao Deng, Li Su, Junling Wang, Hongmei Cui

Melanoma is an aggressive malignant tumor with a poor prognosis. Vemurafenib (PLX4032, vem) is applied to specifically treat BRAF V600E-mutated melanoma patients. However, prolonged usage of vem makes patients resistant to the drug and finally leads to clinical failure. We previously tested the combination regimen of tubulin inhibitor VERU-111 with vem, as well as USP14 selective inhibitor b-AP15 in combination with vem, both of which have showed profound therapeutic effects in overcoming vem resistance in vitro and in vivo. Most importantly, we discovered that vem-resistant melanoma cell lines highly expressed E3 ligase SKP2 and DUB enzyme USP14, and we have demonstrated that USP14 directly interacts and stabilizes SKP2, which contributes to vem resistance. These works give us a clue that USP14 might be a promising target to overcome vem resistance in melanoma. MitoCur-1 is a curcumin derivative, which was originally designed to specifically target tumor mitochondria inducing redox imbalance, thereby promoting tumor cell death. In this study, we have demonstrated that it can work as a novel USP14 inhibitor, and thus bears great potential in providing an anti-tumor effect and sensitizing vem-resistant cells by inducing ferroptosis in melanoma. Application of MitoCur-1 dramatically induces USP14 inhibition and inactivation of GPX4 enzyme, meanwhile, increases the depletion of GSH and decreases SLC7A11 expression level. As a result, ferrous iron-dependent lipid ROS accumulated in the cell, inducing ferroptosis, thus sensitizes the vem-resistant melanoma cell. Interestingly, overexpression of USP14 antagonized all the ferroptosis cascade events induced by MitoCur-1, therefore, we conclude that MitoCur-1 induces ferroptosis through inhibition of USP14. We believe that by inhibition of USP14, vem resistance can be reversed and will finally benefit melanoma patients in future.

黑色素瘤是一种侵袭性恶性肿瘤,预后不良。Vemurafenib (PLX4032, vem)用于特异性治疗BRAF v600e突变的黑色素瘤患者。然而,长期使用vem使患者对药物产生耐药性,最终导致临床失败。我们之前测试了微管蛋白抑制剂VERU-111与vem的联合方案,以及USP14选择性抑制剂b-AP15与vem的联合方案,这两种方案在体外和体内都显示出了深刻的治疗效果,克服了vem的耐药性。最重要的是,我们发现抗vem黑色素瘤细胞系高度表达E3连接酶SKP2和DUB酶USP14,并且我们已经证明USP14直接相互作用并稳定SKP2,这有助于抗vem。这些工作给我们提供了一个线索,即USP14可能是一个有希望的靶点,可以克服黑色素瘤中的vem耐药性。MitoCur-1是姜黄素衍生物,最初设计用于特异性靶向肿瘤线粒体诱导氧化还原失衡,从而促进肿瘤细胞死亡。在这项研究中,我们已经证明它可以作为一种新的USP14抑制剂,因此在提供抗肿瘤作用和通过诱导黑素瘤中的铁下垂致敏em抵抗细胞方面具有很大的潜力。应用MitoCur-1显著诱导USP14抑制和GPX4酶失活,同时增加GSH耗损,降低SLC7A11表达水平。结果,亚铁依赖的脂质ROS在细胞中积累,诱导铁下垂,从而使抗黑色素瘤细胞致敏。有趣的是,USP14的过表达可以拮抗MitoCur-1诱导的所有铁下垂级联事件,因此,我们得出结论,MitoCur-1通过抑制USP14诱导铁下垂。我们相信,通过抑制USP14,可以逆转vem耐药性,并最终使黑色素瘤患者在未来受益。
{"title":"MitoCur-1 induces ferroptosis to reverse vemurafenib resistance in melanoma through inhibition of USP14","authors":"Gege Li,&nbsp;Changlong Zhou,&nbsp;Lu Wang,&nbsp;Yalong Zheng,&nbsp;Bo Zhou,&nbsp;Guoyan Li,&nbsp;Zhongyu Ma,&nbsp;Peng Sun,&nbsp;Yuantao Deng,&nbsp;Li Su,&nbsp;Junling Wang,&nbsp;Hongmei Cui","doi":"10.1111/pcmr.13150","DOIUrl":"10.1111/pcmr.13150","url":null,"abstract":"<p>Melanoma is an aggressive malignant tumor with a poor prognosis. Vemurafenib (PLX4032, vem) is applied to specifically treat BRAF V600E-mutated melanoma patients. However, prolonged usage of vem makes patients resistant to the drug and finally leads to clinical failure. We previously tested the combination regimen of tubulin inhibitor VERU-111 with vem, as well as USP14 selective inhibitor b-AP15 in combination with vem, both of which have showed profound therapeutic effects in overcoming vem resistance in vitro and in vivo. Most importantly, we discovered that vem-resistant melanoma cell lines highly expressed E3 ligase SKP2 and DUB enzyme USP14, and we have demonstrated that USP14 directly interacts and stabilizes SKP2, which contributes to vem resistance. These works give us a clue that USP14 might be a promising target to overcome vem resistance in melanoma. MitoCur-1 is a curcumin derivative, which was originally designed to specifically target tumor mitochondria inducing redox imbalance, thereby promoting tumor cell death. In this study, we have demonstrated that it can work as a novel USP14 inhibitor, and thus bears great potential in providing an anti-tumor effect and sensitizing vem-resistant cells by inducing ferroptosis in melanoma. Application of MitoCur-1 dramatically induces USP14 inhibition and inactivation of GPX4 enzyme, meanwhile, increases the depletion of GSH and decreases SLC7A11 expression level. As a result, ferrous iron-dependent lipid ROS accumulated in the cell, inducing ferroptosis, thus sensitizes the vem-resistant melanoma cell. Interestingly, overexpression of USP14 antagonized all the ferroptosis cascade events induced by MitoCur-1, therefore, we conclude that MitoCur-1 induces ferroptosis through inhibition of USP14. We believe that by inhibition of USP14, vem resistance can be reversed and will finally benefit melanoma patients in future.</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 2","pages":"316-328"},"PeriodicalIF":4.3,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138174997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma CD52 mRNA表达预测黑色素瘤的预后和对免疫检查点阻断的反应。
IF 4.3 3区 医学 Q2 CELL BIOLOGY Pub Date : 2023-11-17 DOI: 10.1111/pcmr.13151
Luka de Vos-Hillebrand, Simon Fietz, Philip Hillebrand, Zsófi Kulcsár, Marie Yatou Diop, Sarah Hollick, Alexander Philippe Maas, Sebastian Strieth, Jennifer Landsberg, Dimo Dietrich

The immune-modulating protein CD52 attenuates lymphocyte function and is associated with autoimmune disorders, for example, multiple sclerosis (MS). CD52 represents a therapeutic target in MS and chronic lymphocytic leukemia (CLL). Its expression has prognostic and predictive value in CLL and is prognostic in breast cancer. Its significance in melanoma is unclear. We analyzed CD52 mRNA expression data from tumor bulk tissues of N = 445 untreated melanoma patients from The Cancer Genome Atlas (TCGA) Research Network and of N = 121 melanoma patients undergoing anti-PD-1 immune checkpoint blockade (ICB) with regard to outcome (overall survival [OS], disease control [DC], and progression-free survival [PFS]), single-cell RNA-Seq data of N = 4645 cells from N = 19 melanoma tissues, and N = 15,457 cells from normal skin provided by N = 5 donors. Higher CD52 mRNA expression was associated with favorable OS (hazard ratio (HR) = 0.820, [95% CI 0.734–0.916], p < .001) in non-ICB-treated melanoma and with PFS (HR = 0.875, [95% CI 0.775–0.989], p = .033) and DC (p = .005) in ICB-treated melanoma. CD52 expression correlated significantly with distinct immune cell subsets and correlated negatively with immune checkpoint expression in T cells. Moreover, our results suggest CD52 expression by a certain type of tissue-resident macrophages. CD52 mRNA was expressed in a small subgroup (8%) of immune checkpoint coexpressing melanoma cells. CD52 expression is associated with features of ICB response in melanoma. Concomitant ICB and anti-CD52 treatment requires critical review.

免疫调节蛋白CD52减弱淋巴细胞功能,并与自身免疫性疾病,如多发性硬化症(MS)有关。CD52是多发性硬化症和慢性淋巴细胞白血病(CLL)的治疗靶点。其表达在CLL和乳腺癌中具有预后和预测价值。它在黑色素瘤中的意义尚不清楚。我们分析CD52 mRNA表达肿瘤体积的数据组织N = 445治疗黑色素瘤患者的癌症基因组图谱(TCGA)研究网络和N = 121黑色素瘤患者接受anti-PD-1免疫检查点封锁(ICB)对结果(总生存期(OS),疾病控制(DC)和无进展生存(PFS)),单细胞RNA-Seq数据从N = 19 N = 4645细胞的黑色素瘤组织,和N = 15457 N = 5捐助者提供的细胞从正常皮肤。较高的CD52 mRNA表达与良好的OS相关(风险比(HR) = 0.820, [95% CI 0.734-0.916], p
{"title":"CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma","authors":"Luka de Vos-Hillebrand,&nbsp;Simon Fietz,&nbsp;Philip Hillebrand,&nbsp;Zsófi Kulcsár,&nbsp;Marie Yatou Diop,&nbsp;Sarah Hollick,&nbsp;Alexander Philippe Maas,&nbsp;Sebastian Strieth,&nbsp;Jennifer Landsberg,&nbsp;Dimo Dietrich","doi":"10.1111/pcmr.13151","DOIUrl":"10.1111/pcmr.13151","url":null,"abstract":"<p>The immune-modulating protein CD52 attenuates lymphocyte function and is associated with autoimmune disorders, for example, multiple sclerosis (MS). CD52 represents a therapeutic target in MS and chronic lymphocytic leukemia (CLL). Its expression has prognostic and predictive value in CLL and is prognostic in breast cancer. Its significance in melanoma is unclear. We analyzed <i>CD52</i> mRNA expression data from tumor bulk tissues of <i>N</i> = 445 untreated melanoma patients from The Cancer Genome Atlas (TCGA) Research Network and of <i>N</i> = 121 melanoma patients undergoing anti-PD-1 immune checkpoint blockade (ICB) with regard to outcome (overall survival [OS], disease control [DC], and progression-free survival [PFS]), single-cell RNA-Seq data of <i>N</i> = 4645 cells from <i>N</i> = 19 melanoma tissues, and <i>N</i> = 15,457 cells from normal skin provided by <i>N</i> = 5 donors. Higher <i>CD52</i> mRNA expression was associated with favorable OS (hazard ratio (HR) = 0.820, [95% CI 0.734–0.916], <i>p</i> &lt; .001) in non-ICB-treated melanoma and with PFS (HR = 0.875, [95% CI 0.775–0.989], <i>p</i> = .033) and DC (<i>p</i> = .005) in ICB-treated melanoma. <i>CD52</i> expression correlated significantly with distinct immune cell subsets and correlated negatively with immune checkpoint expression in T cells. Moreover, our results suggest <i>CD52</i> expression by a certain type of tissue-resident macrophages. <i>CD52</i> mRNA was expressed in a small subgroup (8%) of immune checkpoint coexpressing melanoma cells. <i>CD52</i> expression is associated with features of ICB response in melanoma. Concomitant ICB and anti-CD52 treatment requires critical review.</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 2","pages":"309-315"},"PeriodicalIF":4.3,"publicationDate":"2023-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.13151","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136395483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pigment Cell & Melanoma Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1